Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
In: Annals of Oncology, Jg. 34 (2023-08-01), Heft 8, S. 660-669
academicJournal
Zugriff:
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality of life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor or palbociclib + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is an interactive autonomous application reacting to patient self-reported observations. Between 2017 and 2021, 499 patients (median age 59 years) from 71 centers were randomized (2 : 1, stratified by therapy line) between an active version of CANKADO PRO-React (CANKADO-active arm) and a version with limited functionality (CANKADO-inform arm). A total of 412 patients (271 CANKADO-active; 141 CANKADO-inform) were available for analysis of the primary endpoint, time to deterioration (TTD) of QoL [10-point drop on the Functional Assessment of Cancer Therapy—General (FACT-G) score], using an Aalen–Johansen estimator for cumulative incidence function of TTD DQoL (QoL deterioration) with 95% pointwise confidence intervals (CIs). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and DQoL. In all patients [intention-to-treat (ITT)-ePRO], cumulative incidence of DQoL was significantly more favorable (lower) in the CANKADO-active arm (hazard ratio 0.698, 95% CI 0.506-0.963). Among first-line patients (n = 295), the corresponding hazard ratio was 0.716 (0.484-1.060; P = 0.09), and in second-line patients (n = 117) it was 0.661 (0.374-1.168; P = 0.2). Absolute patient numbers declined in later visits; FACT-G completion rates were 80% and higher until about visit 30. Mean FACT-G scores showed a steady decline from baseline and an offset in favor of CANKADO-active. No significant differences in clinical outcome were observed between arms: median PFS (ITT population) was 21.4 (95% CI 19.4-23.7) (CANKADO-active) and 18.7 (15.1-23.5) months (CANKADO-inform); median OS was not reached (CANKADO-active) and 42.6 months (CANKADO-inform). PreCycle is the first multicenter randomized eHealth trial demonstrating a significant benefit for MBC patients receiving oral tumor therapy when using an interactive autonomous patient empowerment application. • PreCycle evaluated the impact of an autonomous symptom monitoring application on TTD of QoL. • Primary endpoint was TTD of QoL in HR+/HER2- MBC treated with endocrine therapy + palbociclib. • Deterioration of QoL was significantly delayed with interactive CANKADO PRO-React-based ePRO assessment. [ABSTRACT FROM AUTHOR]
Titel: |
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
|
---|---|
Autor/in / Beteiligte Person: | Harbeck, N. ; Fasching, P.A. ; Wuerstlein, R. ; Degenhardt, T. ; Lüftner, D. ; Kates, R.E. ; Schumacher, J. ; Räth, P. ; Hoffmann, O. ; Lorenz, R. ; Decker, T. ; Reinisch, M. ; Göhler, T. ; Staib, P. ; Gluz, O. ; Schinköthe, T. ; Schmidt, M. |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 34 (2023-08-01), Heft 8, S. 660-669 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0923-7534 (print) |
DOI: | 10.1016/j.annonc.2023.05.003 |
Schlagwort: |
|
Sonstiges: |
|